Literature DB >> 9109501

Cell cycle and cancer: critical events at the G1 restriction point.

G DelSal1, M Loda, M Pagano.   

Abstract

In eukaryotic cells, each phase of the cell division cycle is controlled by the sequential activation of various cyclin-dependent kinases (Cdks). These kinases are known to phosphorylate various substrates whose activity is critical for cell cycle progression. As key regulators of the cell cycle, Cdks must be strictly controlled by both extracellular and intracellular signals for adequate responses to occur. There are several distinct molecular mechanisms for controlling the activity of the different Cdks: regulated synthesis and destruction of the activating subunit (cyclin), regulated synthesis and destruction of the inhibitory subunit (Cki), and posttranslational modification of the kinase subunit by highly specific kinases and phosphatases. During the G1 phase of the cell cycle, cells sense, integrate positive and negative signals, and transmit them to the cell cycle machinery. Because of this pivotal role, a vast majority of oncogenic events selectively target elements controlling the G1. In this review we discuss the elements controlling the G1 phase in relationship to the genesis of cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9109501     DOI: 10.1615/critrevoncog.v7.i1-2.80

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  14 in total

1.  SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)-->S progression by controlling the expression and cellular compartmentalization of cyclin D.

Authors:  X Lin; P Nelson; I H Gelman
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

2.  Role of the Cdc25A phosphatase in human breast cancer.

Authors:  M G Cangi; B Cukor; P Soung; S Signoretti; G Moreira; M Ranashinge; B Cady; M Pagano; M Loda
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

3.  Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression.

Authors:  E S Knudsen; C Buckmaster; T T Chen; J R Feramisco; J Y Wang
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

4.  p27 expression in inflammatory bowel disease-associated neoplasia. Further evidence of a unique molecular pathogenesis.

Authors:  S Walsh; M Murphy; M Silverman; R Odze; D Antonioli; H Goldman; M Loda
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

5.  Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases.

Authors:  G V Thomas; K Szigeti; M Murphy; G Draetta; M Pagano; M Loda
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

6.  Arrest of G(1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription.

Authors:  D Guardavaccaro; G Corrente; F Covone; L Micheli; I D'Agnano; G Starace; M Caruso; F Tirone
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 7.  Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.

Authors:  A M Senderowicz
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

8.  Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival.

Authors:  J J Del Pizzo; A Borkowski; S C Jacobs; N Kyprianou
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

9.  Mixed tocotrienols inhibit prostate carcinogenesis in TRAMP mice.

Authors:  Avantika Barve; Tin Oo Khor; Kenneth Reuhl; Bandaru Reddy; Harold Newmark; Ah-Ng Kong
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

10.  Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells.

Authors:  Min Fei; Qinglei Hang; Sicong Hou; Changgeng Ruan
Journal:  Int J Hematol       Date:  2013-09-14       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.